SpringWorks Therapeutics, Inc. announced the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for nirogacestat, an oral, selective, small molecule, gamma-secretase inhibitor, for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.
August 29, 2019
· 6 min read